People · Operator
Named in public records as an officer, director or promoter · active 2016–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Melinta Therapeutics, Inc. /New/ | — | Pharmaceuticals | Series D+ | $346.8M | $4.9B | 2018 |
| Ocugen, Inc. | — | Biotechnology | Series B | $145.6M | $566.9M | 2016 |
David J. Gill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David J. Gill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Johnson | 2 | 25 |
| Garheng Kong | 2 | 16 |
| Michael Lewis | 1 | 12 |
| David Gill | 1 | 8 |
| Kevin Rakin | 1 | 7 |
| Dov Goldstein | 1 | 6 |
| Patrick O'Donnell | 1 | 6 |
| Richard Kent | 1 | 5 |
| John H Johnson | 1 | 4 |
| Adam Gridley | 1 | 4 |
| John L. Johnson | 1 | 3 |
| Kevin McArdle | 1 | 3 |
| Peter Greenleaf | 1 | 3 |
| P. Sherill Neff | 1 | 3 |
| I Wistar Morris | 1 | 3 |
| Joshua Baltzell | 1 | 2 |
| Frank Leo | 1 | 2 |
| Ramesh Kumar | 1 | 2 |
| John Zhang | 1 | 2 |
| Michael L Corrado | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.